Careers
Careers
Shape the future of our company
Welcome to the Quotient careers page.
We currently have a wide array of career opportunities available spanning a variety of professional disciplines, including research and development, manufacturing, quality management, commercial planning, and corporate support functions.


Joining Quotient represents a fantastic opportunity to become part of a team that will shape the future of the company and contribute to efforts to fundamentally transform transfusion diagnostics. If you want to take the next step in your career in a thriving, positive, and collegiate environment, Quotient could be the place for you.

Explore our Organization

Explore our Organization

Have you ever wondered what it is like to work as a member of a cutting-edge team?

Working at Quotient may well be unlike any other job in the world. There’s so much on offer. Innovation. Scientific breakthroughs. New product development and production growth. Lifesaving technology. Not to mention amazing personal and career development opportunities and the staff association nights. Interested?
Learn more

Life at Quotient

We are committed to delivering solutions that drive continual improvement; as such, we incessantly rethink the way in-vitro diagnostics is practiced. Discover what life is like as a member of the Quotient team.
Learn more
Life at Quotient

Love what we do

1
2
3
4

Available positions

Job title
Department
Location
Maintenance & Calibration Technician
Facility
Eysins, Switzerland
View all jobs

Our Hiring Process

Learn how to apply, review resume and interview tips and get answers to frequently asked questions.
Learn more

Latest updates

CEO, Franz Walt on CNN Money CH
News
CNN Money CH: Swiss company races to bring COVID-19 antibody tests to market

Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies.

Financial Times
News
Financial Times: Swiss group says its machines can conduct 30m virus antibody tests this year

Quotient warns global shortages of critical components could hamper efforts

To read the full article, visit: Financial Times

SARS-CoV-2 Microarray
News
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development

JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1

Lab
News
Quotient Limited to Host Investor Information Conference Call and Live Webcast

Link to webcast

 

Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
News
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

JERSEY, Channel Islands, Feb.

Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call
News
Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.

View all